Quantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2

Biomaterials

Volumn 32, Issue 30, 2011, Pages 7592-7599

  Chen, Chuang ^a,b   Sun, Sheng Rong ^c   Gong, Yi Ping ^d   Qi, Chu Bo ^d   Peng, Chun Wei ^a,b   Yang, Xue Qin ^a,b   Liu, Shao Ping ^a,b   Peng, Jun ^e   Zhu, Shan ^c   Hu, Ming Bai ^a,b   Pang, Dai Wen ^f   Li, Yan ^a,b  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^d HUBEI CANCER HOSPITAL   (China)

^e And Wuhan Tumor Nanometer Diagnosis Engineering Research Center   (China)

^f WUHAN UNIVERSITY   (China)

Author keywords

Breast carcinoma; HER2; Hormone receptor; Molecular classification; Quantitative analysis; Quantum dots

Indexed keywords

BREAST CARCINOMAS; HER2; HORMONE RECEPTOR; MOLECULAR CLASSIFICATION; QUANTUM DOT;

DECISION MAKING; DISEASES; ENDOCRINOLOGY; GENE THERAPY; SPECTRUM ANALYSIS;

SEMICONDUCTOR QUANTUM DOTS;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; QUANTUM DOT;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CELL HETEROGENEITY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SPECTROSCOPY;

BREAST NEOPLASMS; FEMALE; HUMANS; MICROSCOPY, FLUORESCENCE; QUANTUM DOTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 80051552664     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.06.029     Document Type: Article

References (66)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Benson J.R., Jatoi I., Keisch M., Esteva F.J., Makris A., Jordan V.C. Early breast cancer. Lancet 2009, 373(9673):1463-1479.
3. Veronesi U., Zurrida S., Goldhirsch A., Rotmensz N., Viale G. Breast cancer classification: time for a change. J Clin Oncol 2009, 27(15):2427-2428.
4. Chen C., Xia H.S., Gong Y.P., Peng J., Peng C.W., Hu M.B., et al. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis. Biomaterials 2010, 31(33):8818-8825.
5. Park Y.H., Lee S.J., Cho E.Y., Choi Y.L., Lee J.E., Nam S.J., et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol 2011, 22(7):1554-1560.
6. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25(33):5287-5312.
7. Cianfrocca M., Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin 2009, 59(5):303-313.
8. Harbeck N., Salem M., Nitz U., Gluz O., Liedtke C. Personalized treatment of early-stage breast cancer: present concepts and future directions. Cancer Treat Rev 2010, 36(8):584-594.
9. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
10. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20(8):1319-1329.
11. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14(4):320-368.
12. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S., et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28(16):2784-2795.
13. Fisher B., Redmond C.K., Fisher E.R. Evolution of knowledge related to breast cancer heterogeneity: a 25-year retrospective. J Clin Oncol 2008, 26(13):2068-2071.
14. Di Cosimo S., Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. Nat Rev Clin Oncol 2010, 7(3):139-147.
15. Oakman C., Santarpia L., Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 2010, 7(12):725-732.
16. Kravchenko J., Akushevich I., Seewaldt V.L., Abernethy A.P., Lyerly H.K. Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. Breast Cancer Res Treat 2011, 128(2):483-493.
17. Tripathy D. Are we hitting the right combination for hormonally sensitive breast cancer?. J Clin Oncol 2009, 27(16):2580-2582.
18. Gnant M., Steger G.G. Fighting overtreatment in adjuvant breast cancer therapy. Lancet 2009, 374(9707):2029-2030.
19. Bedard P.L., Cardoso F. Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?. Nat Rev Clin Oncol 2011, 8(5):272-279.
20. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9(9):631-643.
21. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011, 62:233-247.
22. Royston P., Sauerbrei W. Interactions between treatment and continuous covariates: a step toward individualizing therapy. J Clin Oncol 2008, 26(9):1397-1399.
23. Chen C., Peng J., Xia H.S., Yang G.F., Wu Q.S., Chen L.D., et al. Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials 2009, 30(15):2912-2918.
24. Chen C., Peng J., Xia H.S., Wu Q.S., Zeng L.B., Xu H., et al. Quantum dots-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity. Nanotechnology 2010, 21(9):95101.
25. Leyland-Jones B., Colomer R., Trudeau M.E., Wardley A., Latreille J., Cameron D., et al. Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J Clin Oncol 2010, 28(6):960-966.
26. Oude M.T.H., Dijkers E.C., Netters S.J., Lub-de Hooge M.N., Brouwers A.H., Haasjes J.G., et al. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. J Clin Oncol 2010, 28(21):e355-e356.
27. Joensuu H., Sperinde J., Leinonen M., Huang W., Weidler J., Bono P., et al. Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol 2011, 10.1093/annonc/mdq710.
28. Bates M., Sperinde J., Kostler W.J., Ali S.M., Leitzel K., Fuchs E.M., et al. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Ann Oncol 2011, 10.1093/annonc/mdq706.
29. Mackey J.R. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?. J Clin Oncol 2011, 29(12):1504-1506.
30. Stendahl M., Ryden L., Nordenskjold B., Jonsson P.E., Landberg G., Jirstrom K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006, 12(15):4614-4618.
31. Colleoni M., Bagnardi V., Rotmensz N., Gelber R.D., Viale G., Pruneri G., et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 2009, 116(2):359-369.
32. Regierer A.C., Wolters R., Kurzeder C., Wockel A., Novopashenny I., Possinger K., et al. High estrogen receptor expression in early breast cancer: chemotherapy needed to improve RFS?. Breast Cancer Res Treat 2011, 128(1):273-281.
33. Perez E.A. Breast cancer management: opportunities and barriers to an individualized approach. Oncologist 2011, 16(Suppl 1):20-22.
34. Rakha E.A., Reis-Filho J.S., Ellis I.O. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 2010, 120(2):293-308.
35. Nadji M., Gomez-Fernandez C., Ganjei-Azar P., Morales A.R. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005, 123(1):21-27.
36. De Maeyer L., Van Limbergen E., De Nys K., Moerman P., Pochet N., Hendrickx W., et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?. J Clin Oncol 2008, 26(2):335-336.
37. Allred D.C. Problems and solutions in the evaluation of hormone receptors in breast cancer. J Clin Oncol 2008, 26(15):2433-2435.
38. Collins L.C., Botero M.L., Schnitt S.J. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol 2005, 123(1):16-20.
39. Viale G., Regan M.M., Maiorano E., Mastropasqua M.G., Golouh R., Perin T., et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 2008, 26(9):1404-1410.
40. Wilson C., Rong H.M., Bauerfeind I., Felber M., Wang H.J., Beryt M., et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003, 95(2):142-153.
41. Badve S.S., Baehner F.L., Gray R.P., Childs B.H., Maddala T., Liu M.L., et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008, 26(15):2473-2481.
42. Mazouni C., Bonnier P., Goubar A., Romain S., Martin P.M. Is quantitative oestrogen receptor expression useful in the evaluation of the clinical prognosis? Analysis of a homogeneous series of 797 patients with prospective determination of the ER status using simultaneous EIA and IHC. Eur J Cancer 2010, 46(15):2716-2725.
43. Pagani O., Gelber S., Simoncini E., Castiglione-Gertsch M., Price K.N., Gelber R.D., et al. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009, 116(3):491-500.
44. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
45. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100(14):8418-8423.
46. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003, 100(18):10393-10398.
47. Loi S., Piccart M., Sotiriou C. The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit Rev Oncol Hematol 2007, 61(3):187-194.
48. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360(8):790-800.
49. Weigelt B., Baehner F.L., Reis-Filho J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220(2):263-280.
50. Oesterreich S., Lee A.V., Davidson N.E. Is it time to ReSET the standard for estrogen receptor testing in breast cancer. J Clin Oncol 2010, 28(27):4101-4103.
51. Mackay A., Weigelt B., Grigoriadis A., Kreike B., Natrajan R., A'hern R., et al. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst 2011, 103(8):1-12.
52. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826.
53. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24(23):3726-3734.
54. Goldstein L.J., Gray R., Badve S., Childs B.H., Yoshizawa C., Rowley S., et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008, 26(25):4063-4071.
55. Albain K.S., Barlow W.E., Shak S., Hortobagyi G.N., Livingston R.B., Yeh I.T., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11(1):55-65.
56. Mamounas E.P., Tang G., Fisher B., Paik S., Shak S., Costantino J.P., et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010, 28(10):1677-1683.
57. Dowsett M., Cuzick J., Wale C., Forbes J., Mallon E.A., Salter J., et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010, 28(11):1829-1834.
58. Toi M., Iwata H., Yamanaka T., Masuda N., Ohno S., Nakamura S., et al. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer 2010, 116(13):3112-3118.
59. Tang G., Shak S., Paik S., Anderson S.J., Costantino J.P., Geyer C.E., et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011, 127(1):133-142.
60. Partin J.F., Mamounas E.P. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer. Ann Surg Oncol 2011, 10.1245/s10434-011-1698-z.
61. Geffen D.B., Abu-Ghanem S., Sion-Vardy N., Braunstein R., Tokar M., Ariad S., et al. The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. Ann Oncol 2011, 10.1093/annonc/mdq769.
62. Staaf J., Ringner M., Vallon-Christersson J., Jonsson G., Bendahl P.O., Holm K., et al. Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010, 28(11):1813-1820.
63. Knauer M., Cardoso F., Wesseling J., Bedard P.L., Linn S.C., Rutgers E.J., et al. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 2010, 103(12):1788-1793.
64. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N Engl J Med 2010, 363(20):1938-1948.
65. Hudis C.A., Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011, 16(Suppl 1):1-11.
66. Bonilla L., Ben-Aharon I., Vidal L., Gafter-Gvili A., Leibovici L., Stemmer S.M. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 2010, 102(24):1845-1854.